Objectives The objective of this study is to investigate the incidence and clinical implications of thrombus on baseline angiography among patients presenting with non-ST-segment elevation acute coronary syndromes (ACS) undergoing percutaneous coronary intervention (PCI).
Pre-procedural thrombus is a harbinger of procedural complications following primary percutaneous coronary intervention (PCI) for ST-segment elevation myocardial infarction (MI) (1) (2) (3) . Thrombus can lead to poor outcomes by various mechanisms including distal embolization, impaired myocardial perfusion, increased myocardial necrosis and decreased left ventricular function (4, 5) , with subsequent reduced survival benefit at follow-up (6 -8) . The purpose of this study is to determine the incidence, predictors and prognosis of pre-procedural thrombus among moderate-and high-risk acute coronary syndromes (ACS) patients undergoing contemporary guidelinerecommended PCI in the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial (9 -12) .
Methods

Study population and design.
The design and results of the ACUITY trial have been previously published (12, 13) . Briefly, 13,819 patients with moderate-and highrisk ACS were randomized in an open-label fashion to 1 of 3 antithrombotic regimens: heparin (unfractionated or enoxaparin at site discretion) plus a glycoprotein IIb/ IIIa inhibitor (GPI), bivalirudin plus a GPI, or bivalirudin monotherapy. Patients assigned to heparin plus a GPI or bivalirudin plus a GPI were randomly assigned again in a 2-by-2 factorial design to either upstream or deferred initiation. In patients assigned to bivalirudin monotherapy, GPI administration was reserved for "bail-out" use for procedural PCI complications or suboptimal results. Coronary angiography was required per protocol within 72 h of randomization, with subsequent triage to treatment with PCI, coronary artery bypass grafting (CABG), or medical management at the physician's discretion. The study was approved by the institutional review board or ethics committee at each participating center, and all patients signed written informed consent. Angiographic analysis. Comprehensive quantitative coronary angiography of baseline and final angiograms from 6,921 consecutive patients from the U.S. centers was performed by an independent angiographic core laboratory. All angiograms were evaluated by reviewers blinded to treatment assignment using validated quantitative methods (Medis, Leiden, the Netherlands). Complete baseline and post-procedural angiographic data were available in 3,627 patients undergoing PCI. Coronary thrombus was defined as an intraluminal filling defect or an area of contrast staining noted within the target stenosis. Thrombus burden was assessed as the total area based on the diameter and length of the observed angiographic thrombus. Abrupt closure was defined as a decrease in Thrombolysis In Myocardial Infarction (TIMI) flow to grade 0 or 1 with recurrent stenosis similar to or worse than that present before PCI. No-reflow was defined as reduced antegrade flow (TIMI flow grade Ͻ2) in the absence of occlusion at the treatment site or evidence of distal embolization. Distal embolization was defined as the migration of a filling defect to distally occlude the infarct-related vessel or 1 of its branches, or a new abrupt cutoff of the distal vessel or its branch. Other variables included baseline TIMI flow grade and myocardial blush score assessed on a scale of 0 to 3 using methods previously described (14, 15) . The extent of coronary artery disease (CAD) was quantified by an angiographic surrogate of disease burden (the total length in millimeters of all lesions with a Ͼ30% diameter stenosis in a major epicardial vessel), and the Duke Jeopardy Score estimating the amount of myocardium at risk on the basis of the particular location of coronary artery stenosis, in which a higher score corresponds to a greater area of jeopardized myocardium (16) . Definitions and statistical analyses. The endpoints of this analysis included: 1) composite ischemia (defined as death from any cause, MI, or unplanned revascularization for ischemia); 2) definite or probable stent thrombosis (ST) at 30 days and at 1 year; and 3) non-CABG-related major bleeding; and 4) net adverse clinical event (composite ischemia or non-CABG-related major bleeding) at 30 days. The definitions of clinical endpoints have been previously described (13 Research Consortium criteria (17) . We compared baseline characteristics and outcomes according to the presence of thrombus and assessed the independent impact of thrombus on 30-day and 1-year outcomes. Furthermore, we evaluated the effect of antithrombin therapy on composite ischemia or non-CABG-related bleeding in patients with thrombus. All endpoints were adjudicated by a clinical events committee blinded to the treatment assignment.
Continuous variables were compared using the KruskalWallis test. Categorical values were compared by the chisquare or Fisher's exact test. For comparison of cumulative 30-day and 1-year outcomes between the 2 groups, we used Kaplan-Meier survival analysis and the log-rank test. Cox proportional hazard regression analysis was performed to determine the predictors of: 1) pre-procedural thrombus; and 2) individual components of composite ischemia, major bleeding, and ST. The following variables considered for the pre-procedural thrombus model included: age (per 10-year increment), sex, diabetes, insulin-treated diabetes, hypertension, hyperlipidemia, current smoking, previous MI, previous PCI, previous CABG, chronic renal insufficiency, baseline anemia, planned GPI use (bivalirudin or heparin plus a GPI) versus planned non-GPI use (bivalirudin monotherapy), aspirin or thienopyridine on admission or pre-procedure, duration from first study drug to angiogram, number of diseased vessels, extent of CAD (per 10-mm increment of lesions Ͼ30%), right CAD versus non-right CAD, reference vessel diameter, proximal lesion. Variable for the components of composite ischemia, major bleeding, and ST included: thrombus, age (per 10-year increment), sex, diabetes, insulin-treated diabetes, hypertension, hyperlipidemia, current smoking, previous MI, previous PCI, previous CABG, renal insufficiency, baseline anemia, baseline white blood cell count (per 1,000 increase), left ventricular ejection fraction (per 10% increase), biomarker elevation, ST-segment deviation, bivalirudin plus a GPI (vs. heparin plus a GPI), bivalirudin alone (vs. heparin plus a GPI), extent of CAD, number of diseased vessels, left anterior descending artery disease, proximal lesion, baseline TIMI flow grade, baseline blush score, eccentricity, ulceration, aneurysm, moderate-to-severe calcification, presence or absence of collaterals, worst percent diameter stenosis, stent type (drug-eluting stent [DES] vs. bare-metal stent [BMS]), use of Ն2 stents, aspiration device use, distal protection device use, aspirin at discharge, and thienopyridine at discharge.
To evaluate the relation between thrombus burden and ST, patients with measurable thrombus area (n ϭ 432, 81.5%) were divided into tertiles of thrombus area (Յ17 mm 2 , n ϭ 156; 17 to 32 mm 2 , n ϭ 135; and Ͼ32 mm 2 , n ϭ 141). All analyses were based on intention to treat. The p values, odds ratios (OR), and corresponding 2-sided 95% confidence intervals (CI) for predictors are presented.
Results
Baseline characteristics. Pre-procedural thrombus was present in 530 (15%) patients. Patients with thrombus were younger, were more frequently male, had lower prevalence of comorbidities including diabetes, hypertension, hyperlipidemia, and chronic renal insufficiency, and had less previous MI and PCI (Table 1) . Current smoking, baseline troponin elevation, and ST-segment deviation was more common in patients with thrombus. Study drug and procedural characteristics. The bail-out use of GPI in the bivalirudin monotherapy group was more frequent in patients with thrombus versus without thrombus (17.3% vs. 6.5%, p Ͻ 0.0001) ( Table 2 ). BMS use was significantly higher in patients with thrombus than those without thrombus. Although thrombus aspiration or distal protection device were used more frequently in patients with thrombus, overall usage was low. Among patients with thrombus, those treated with versus without thrombus aspiration had similar rates of composite ischemia at 30 days (14.1% vs. 12.9%, p ϭ 0.81) and at 1 year (22.7% vs. 21.8%, p ϭ 0.72). Medication use after discharge was similar between the 2 groups, except for greater use of beta-blockers in the thrombus group (83.4% vs. 77.3%, p ϭ 0.002). Baseline and final angiographic characteristics. Left ventricular ejection fraction was lower in patients with thrombus than 
Effects of antithrombotic regimens on clinical outcomes in
patients with thrombus. Among the 530 patients with thrombus, antithrombotic treatment allocation included heparin plus a GPI (n ϭ 163), bivalirudin plus a GPI (n ϭ 170), or bivalirudin alone (n ϭ 197). Major bleeding at 30 days was reduced by 60% with bivalirudin alone compared with heparin plus a GPI (Table 5 ). There was no difference in 30-day and 1-year net adverse clinical events or composite ischemia among antithrombin groups ( Table 5 ). The use of bail-out GPI in the bivalirudin monotherapy group did not affect composite ischemia at 30 days (11.8% vs. 16.6%, p ϭ 0.48) or at 1 year (20.7% vs. 19.7%, p ϭ 0.90). Among the 170 patients with thrombus receiving bivalirudin plus a GPI, the assignment to upstream versus deferred GPI therapy resulted in a significant reduction in 1-year composite ischemia (13.1% vs. 27.4%, p ϭ 0.03) and MI (9.0% vs. 21.2%, p ϭ 0.03) ( Table 6 ).
Discussion
Thrombotic lesions remain a common finding in patients with moderate-and high-risk ACS undergoing early an- giography and triage to PCI. The presence of thrombus increases procedural complications, likely explaining the associated ischemic complications. Baseline lesion thrombus predicted 30-day mortality, MI, and ST, as well as cumulative MI and ST 1 year following PCI, with more than a 2-fold increased risk of death or ST and 1.5 times risk of MI at 30 days. Paradoxically, baseline thrombus identifies a population with lower risk of mortality and need for unplanned revascularization between 30 days to 1 year.
Planned GPI and thienopyridine use on admission predicted less thrombus, but the antithrombotic regimen did not affect ischemic outcomes of patients with thrombus. Bivalirudin monotherapy reduced bleeding complications, and for those patients with thrombus, upstream use of GPI (vs. deferred GPI) on a background of bivalirudin monotherapy reduced 1-year composite ischemia and MI. Prevalence of thrombus on baseline angiography. Previous studies have reported an incidence of thrombus ranging from 7% to 23% in patients with unstable angina (1,18 -20) , depending on disease acuity, epicardial blood flow, cardiac marker elevation, and the timing of angiography (1, 7, 18, 21) . Consistent with prior studies, larger vessel diameter, right CAD, higher Jeopardy Score, and active smoking history predicted thrombotic lesions (21, 22) . In addition, the planned use of GPI (non-bail out) was associated with a 20% lower frequency of pre-procedural lesion thrombus (22, 23) . Shorter 90-min infusions of intravenous GPI have also shown benefit in reducing thrombus (21) , and our study shows that the benefits of planned GPI can be seen with shorter infusions yet, with the median time from first study drug to PCI in ACUITY being 2.9 h (9,10). Although planned GPI use reduced the occurrence of thrombus, there was no significant difference noted in ischemic outcomes from any of the 3 antithrombotic regimens tested (24) . Treatment and procedural results. Consistent with previous studies, procedural failure and complications, including abrupt closure, distal embolism, reduced epicardial and myocardial perfusions, and slow flow remained higher in patients with thrombus even after the introduction of a stent or GPI (1, 7) , and likely contribute to the increased 30-day ischemic complications (25) and mortality (21,22,26 -28) . The landmark analysis demonstrated that the negative clinical impact of thrombotic lesions appears to be limited to the first 30 days, during which patients with thrombus had significantly higher composite ischemia following PCI, with a 3-fold increase in mortality and a 1.5-fold increase in MI rate. Additional pharmacological interventions and/or mechanical devices should be studied to prevent or treat intracoronary thrombus. Pre-procedural thrombus and clinical outcome. The presence of baseline thrombus worsens the clinical presentation of patients with more frequent troponin elevation (1, 18) , but paradoxically, was comprised of a lower-risk population characterized by younger age, less diabetes, hypertension, hyperlipidemia, renal insufficiency, and history of prior MI or PCI than patients without thrombus, which likely explains the lower event rate seen in the landmark analysis between 30 days and 1 year. Nevertheless, after adjusting for Abbreviations as in Tables 1 and 2 . The presence of thrombus has been clearly identified as a factor predisposing to ST (23, 29) , and in ACUITY, we show a more than 2-fold increase in acute and subacute ST despite contemporary PCI, optimal GPI, and antiplatelet therapy, but no relationship with thrombus burden in contrast to a prior report (7) . Beyond 30 days, there was no apparent added risk of late ST as a result of the initial thrombotic lesion. The absence of persistent risk beyond 30 days would suggest that this population is not at long-term systemic thrombotic risk but rather subject to an acute thrombogenic mechanism likely localized to a ruptured plaque. Considering the significant early ischemic risk, patients with thrombotic lesions on initial angiography may well benefit from optimal antiplatelet pre-loading and may justify the use of more potent thienopyridines (30) .
Effects of antithrombotic treatments on outcomes in patients
with thrombus. The selection of the antithrombotic regimen (heparin plus a GPI vs. bivalirudin plus a GPI vs. bivalirudin monotherapy) did not impact subsequent ischemic events among patients with thrombus. Although bivalirudin monotherapy reduced bleeding complications, the planned upstream use of GPI did appear to have a role in reducing both the frequency of thrombus formation, as well as ischemic complications in thrombotic patients. These benefits were offset by higher bleeding consequences at the systemic GPI doses tested. Whether localized intracoronary dosing of GPI may afford ischemic benefit for thrombotic patients without raising the bleeding risk remains to be evaluated. Study limitations. This study is a retrospective analysis, and is therefore hypothesis generating. The study results only apply to the specific population evaluated. The incidence of thrombus in the study is likely underestimated due to the imperfect sensitivity of angiography in detecting thrombus (2) , and thrombus burden modification related to pre-procedural pharmacotherapy cannot be excluded (18) . Further, the evaluation of antithrombotic regime on clinical outcomes is a subset analysis of this subgroup and is entirely hypothesis generating, but provides insight into possible pharmacological alternatives to prevent or treat intra-coronary thrombus.
Conclusions
Pre-procedural thrombus remains common (15%) among moderate-and high-risk ACS patients undergoing contemporary PCI. Baseline thrombus predicted 30-day ischemic complications, including a 3-fold increased mortality risk. Beyond 30 days, ischemic and mortality complications were reduced, suggesting absence of persistent thrombotic risk. Further evaluation of adjunctive pharmacology is needed to reduce ischemic complications in this high-risk population.
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